Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)
About
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to stimulate translation of scientific discoveries and engineering developments in imaging, data science and/or spectroscopic technologies into methods or tools that address contemporary problems in understanding the fundamental biology, potential risk of development, diagnosis, treatment, and/or disease status for cancer or other disease.
The Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems grant, offered by the National Cancer Institute (NCI), is designed for organizations seeking to bridge the gap between scientific discovery and real-world clinical application. This program specifically funds the translation of advances in imaging, data science, and spectroscopic technologies into practical methods and tools that address critical challenges in cancer and other disease understanding, diagnosis, treatment, and monitoring. The grant is ideal for academic institutions, industrial partners, and eligible organizations including HBCUs, Hispanic-serving institutions, Alaska Native and Native Hawaiian serving institutions, and other underrepresented groups in research. Entrepreneurs and research leaders should apply if they have innovative imaging or data science technologies ready for validation and clinical translation. This R01 Clinical Trial Optional mechanism supports collaborative partnerships that can accelerate the pathway from bench to bedside, making it an excellent opportunity for organizations committed to advancing precision medicine and improving patient outcomes through cutting-edge diagnostic and therapeutic imaging solutions.
Funding Facts
● Applications openDeadline
January 7, 2027
Award Amount
Up to $500K
Who can apply
Last verified July 5, 2026 · Source: Grants.gov
Grant Details
Grant Amount
Up to $500K
Deadline
2027-01-07
Grant Type
federal
Application Cycle
Annual - Deadline January 7, 2027
Best For
Academic institutions, industrial partners, HBCUs, minority-serving institutions, and organizations with innovative imaging and data science technologies ready for clinical translation
Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Govern
Frequently Asked Questions
Who is eligible for Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)?
Eligible applicants include Alaska Native and Native Hawaiian serving institutions, Asian American Native American Pacific Islander serving institutions (AANAPISIs), eligible federal agencies, faith-based and community-based organizations, Hispanic-serving institutions, Historically Black Colleges and Universities (HBCUs), and Indian/Native American tribal governments. Academic institutions and industrial partners can collaborate on this program. For a complete and current list of eligible applicant types, visit the official NCI NOFO website.
How much funding does Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional) provide?
Funding ranges from N/A to $500,000 per award. The specific amount awarded may vary depending on project scope, complexity, and whether a clinical trial component is included. Applicants should review the official NCI funding announcement for detailed budget guidelines and allowable costs.
How do I apply for Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)?
Applications must be submitted through the official NCI Notice of Funding Opportunity (NOFO) portal. The application process typically requires submission of a research proposal, detailed budget, institutional support documentation, and evidence of academic-industrial partnership collaboration. Visit the NCI website at cancer.gov for the specific application deadline (January 7, 2027), submission requirements, and step-by-step instructions. Contact the NCI program officer listed in the NOFO if you have questions about eligibility or the application process.
What can Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional) funding be used for?
Funds support the translation and validation of imaging, data science, and spectroscopic technology innovations into practical clinical methods and tools. Eligible uses include research to advance cancer and disease understanding, risk assessment, diagnosis, treatment monitoring, and disease status evaluation. Projects may involve technology development, validation studies, and optionally, clinical trials. Funds can support personnel, equipment, supplies, and other direct research costs consistent with NCI guidelines. Review the NOFO for detailed allowable expense categories and any restrictions.
Last updated: July 5, 2026